In the meantime, a new study from Chicago – Sener ea- confirms yet again that, amongst breast cancer survivors, “HRT users developed breast cancer at a younger age than nonusers. HRT use was associated with the development of biologically more favorable cancers than those that developed in nonusers; and overall and disease-free survival rates were higher in HRT users than nonusers. HRT users had half the risk of death versus nonusers (hazard ratio = .44, 95% confidence limit = .26 to .73, P = .002) .
And metformin- which in appropriate dose to tolerance halves mortality from type 2 diabetes, and halves new diabetes, and reduces cancer in diabetics, is now being tested in Italy as another anticancer agent in breast cancer sufferers.
So the increasingly overweight from children upwards need metformin; and no postmenopausal woman should go without some appropriate balancing HRT amongst her three-score supplements. .